Biogen building work delayed  

Work on building USD 350 million plant delayed, though Biogen confident of completion on schedule

The start of work on building Biogen's new USD 350 million plant in Medicon Valley – its first production unit outside the US – has been delayed due to problems with the ground, reports Berlingske Tidende Online. Despite the delay however, Biogen is confident that the new plant can be completed on schedule in 2005. This is because the construction is an exact copy of the company's existing production plant in North Carolina.


Since its foundation in 1978 Biogen has been building a world scale operation with capabilities to develop, manufacture, and market its own products. A major step in that process is the new production facility in Denmark. The plant will initially produce Interferon for the treatment of multiple sclerosis, with further products currently under development being added over time. Up to 400 new jobs are expected to be created.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×